| Ytd | -42.52% | |
| 1y | -70.53% |
| Open | 0.88 | Prev Close | 0.88 | Low | 0.85 | High | 0.93 | Mkt Cap | 256.43M |
| Vol | 10.40M | Avg Vol | 5.65M | EPS | -0.12 | P/E | N/A | Forward P/E | -7.15 |
| Beta | 0.26 | Short Ratio | 4.71 | Inst. Own | 27.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 1.14 | 200-d Avg | 1.31 | 1yr Est | 5.50 |
AKBA News
Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's
U.S. stock futures mixed, Dow up 100+ points. Western Digital falls after earnings beat expectations
SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates
Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.02 per share versus the Zacks Consen
Akebia Therapeutics NASDAQ: AKBA reported second-quarter revenue growth for its Vafseo anemia treatm
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday&
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.03) per share which beat the anal
Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million ; more than 10,500 p atient
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a bi
Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a b
CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today
CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a bio
HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ:AKBA) wit
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better th
Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due
Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the
CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a bio
Akebia Therapeutics NASDAQ: AKBA outlined its commercial priorities for Vafseo, the expected evoluti
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a b
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biop
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.03 per share versus the Zacks Consen
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.03) per share which met the analy
Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million ; Q1 2026 total net product
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biop
"The win statistics analysis highlighted favorable outcomes and potential clinical differentiati
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biop
Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass.
EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.
